Institute for Immunity and Transplantation, University College London, United Kingdom.
Clinical and Experimental Medicine, Brighton and Sussex Medical School, United Kingdom.
J Infect Dis. 2019 Jun 19;220(2):228-232. doi: 10.1093/infdis/jiz089.
A human cytomegalovirus (HCMV) vaccine is urgently needed to protect against primary infection and enhance existing immunity in HCMV-infected individuals (HCMV+). Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients prior to transplant, we investigated the composition of the immune response. Vaccination boosted preexisting humoral responses in our HCMV+ cohort but did not promote de novo responses against novel linear epitopes. This suggests that prior natural infection has a profound effect on shaping the antibody repertoire and subsequent response to vaccination ("original antigenic sin"). Thus, vaccination of HCMV+ may require strategies of epitope presentation distinct from those intended to prevent primary infection.
人巨细胞病毒 (HCMV) 疫苗的研发迫在眉睫,其目的是预防原发性感染并增强已感染 HCMV 个体(HCMV+)的现有免疫力。本研究使用 HCMV+糖蛋白 B/MF59 疫苗受种者移植前的血清,调查了免疫反应的组成。疫苗接种增强了我们的 HCMV+队列中预先存在的体液反应,但并未促进针对新线性表位的新反应。这表明先前的自然感染对塑造抗体库以及随后对疫苗接种的反应(“原始抗原性偏倚”)有深远影响。因此,HCMV+的疫苗接种可能需要与预防原发性感染不同的表位呈递策略。